HLB Pharma Falls 7.8% on October 2, Extending Three-Day Decline After 60% Rally on FDA Approval
According to Financial News, HLB Pharma shares fell 7.8% in early trading on October 2, continuing a three-day decline. The stock had surged over 60% in just four trading days following FDA approval of cholangiocarcinoma
HLB Pharma-5.53%
GateNews·10-02 00:37
